<?xml version="1.0" encoding="UTF-8"?>
<p>K.A. has received honoraria and research funding from Eisai Co., Ltd. M.O. has received research funding from Eisai Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Zenyaku Kogyo Co., Ltd., Chugai Pharmaceutical Co., Ltd., Pfizer Japan Inc., Janssen Pharmaceutical K.K., GlaxoSmithKline K.K., MSD K.K., AstraZeneca K.K., Takeda Pharmaceutical Company Limited, Symbio Pharmaceuticals Limited, Solasia Pharma K.K., Mundipharma K.K., Celgene K.K., and Sumitomo Dainippon Pharma Co., Ltd. T.U. has received research funding from Eisai Co., Ltd. K.T. has received research funding from Eisai Co., Ltd., Mundipharma K.K., Celgene K.K., Solasia Pharma K.K., Kyowa Hakko Kirin Co., Ltd., and HUYA Bioscience International. D.M. has received honoraria from Eisai Co., Ltd and Takeda Pharmaceutical Co., Ltd. M.N. and T.N. are employees of Eisai Co., Ltd. K.O. has no conflict of interest.</p>
